Condition
    Moderate Evidence
    Effectiveness 2/5

    Folate (Vitamin B9) for Ischemic Stroke

    A small, population-dependent effect that does not substitute for blood pressure and lipid control.

    Overview

    A small, population-dependent effect that does not substitute for blood pressure and lipid control.

    Verdict

    Mixed evidence

    Folic acid lowers homocysteine and produced a modest stroke reduction in folate-unfortified populations, with little effect where fortification exists.

    How It Works

    Folate is the methyl donor for remethylation of homocysteine to methionine. Elevated homocysteine damages vascular endothelium, promotes oxidative stress and increases thrombogenicity, and folic acid reliably lowers it by around 25%. Whether lowering homocysteine reduces vascular events is the question the trials tested.

    Dosing & Protocol

    Typical dose

    Recommended dose
    0.8 mg daily of folic acid, with B12 status checked first
    Expected timeframe
    Homocysteine falls within weeks; trial benefits emerged only after 3 or more years

    Protocol

    form
    Folic acid tablet, alone or combined with B6 and B12 where homocysteine is raised
    duration
    Long-term; primary-prevention trials ran 4-5 years
    co factor
    Confirm B12 status before starting. Folate is an add-on to blood pressure control, statin therapy and antiplatelet treatment, never a replacement
    titration
    No titration; the CSPPT trial used 0.8 mg daily combined with enalapril in a non-fortified population
    starting dose
    0.8 mg folic acid daily with food

    Evidence

    What the studies say

    The HOPE-2 and VISP trials found no significant stroke reduction with B vitamin therapy in North American populations, where mandatory folic acid fortification of grain already raises baseline folate status. The CSPPT trial in China, a population without fortification, randomised over 20,000 hypertensive adults to enalapril with or without folic acid and found a 21% relative reduction in first stroke. Meta-analyses reconcile these results: the benefit concentrates in folate-deficient populations, in those with low baseline folate, and where trial duration exceeded three years. The absolute effect is modest even where present. Practically, this means correcting genuine folate deficiency is worthwhile, particularly alongside B12 status, but adding folic acid to a replete diet in a fortified country is unlikely to change stroke risk.

    No studies are yet linked to both Folate (Vitamin B9) and Ischemic Stroke.

    Safety

    Caveats

    Folic acid can mask B12 deficiency while allowing neurological damage to progress — always check B12 first. High-dose folic acid may interact with methotrexate and some antiepileptics.

    Less likely to help if

    People in countries with mandatory folic acid fortification and normal baseline folate, where trials showed no benefit.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.